Valuation: RemeGen Co., Ltd.

Capitalization 50.32B 56.94B 7.28B 6.15B 5.61B 5.34B 9.93B 661B 10.3B 65.14B 25.89B 318B 27.32B 26.76B 1,118B P/E ratio 2025 *
-147x
P/E ratio 2026 * 22.4x
Enterprise value 52.28B 59.15B 7.57B 6.38B 5.82B 5.55B 10.31B 687B 10.7B 67.67B 26.9B 331B 28.38B 27.8B 1,162B EV / Sales 2025 *
17.7x
EV / Sales 2026 * 9.78x
Free-Float
55.89%
Yield 2025 *
-
Yield 2026 * -
1 day+0.56%
1 week+2.60%
Current month-4.10%
1 month-14.32%
3 months-5.50%
6 months+4.73%
Current year+12.15%
1 week 78.4
Extreme 78.4
85.95
1 month 76.8
Extreme 76.8
99.2
Current year 71.55
Extreme 71.55
106.6
1 year 14.96
Extreme 14.96
126.6
3 years 10.2
Extreme 10.2
126.6
5 years 10.2
Extreme 10.2
145.5
10 years 10.2
Extreme 10.2
149.8
Manager TitleAgeSince
Chief Executive Officer 64 03/07/2008
Director of Finance/CFO 55 27/09/2023
Corporate Secretary 60 10/05/2020
Director TitleAgeSince
Director/Board Member 64 03/07/2008
Director/Board Member 71 03/07/2008
Director/Board Member 56 10/05/2020
Change 5d. change 1-year change 3-years change Capi.($)
+0.56%+2.60%+416.97%+40.56% 7.27B
-1.55%+0.32%+14.81%+98.80% 51.48B
-2.85%+4.17%+71.33%+17.21% 44.3B
+1.77%-0.74%+87.56%+628.81% 31.72B
+0.10%-0.70%-11.65%-28.28% 26.57B
+1.25%+7.48%+73.82%-33.00% 21.17B
-1.76%-3.13%+23.95%-31.89% 18.64B
-1.43%-2.50%+126.08% - 12.49B
-0.09%+4.26%+74.75%+143.24% 12.41B
+2.26%-0.20%-30.00%+547.62% 11.54B
Average -0.18%+1.22%+84.76%+153.67% 23.76B
Weighted average by Cap. -0.60%+1.40%+57.19%+142.80%

Financials

2025 *2026 *
Net sales 2.96B 3.35B 429M 362M 330M 314M 584M 38.91B 606M 3.83B 1.52B 18.73B 1.61B 1.57B 65.77B 5.24B 5.92B 758M 639M 583M 556M 1.03B 68.82B 1.07B 6.78B 2.69B 33.13B 2.84B 2.78B 116B
Net income -271M -307M -39.25M -33.11M -30.21M -28.8M -53.5M -3.56B -55.5M -351M -140M -1.72B -147M -144M -6.02B 1.78B 2.01B 258M 217M 198M 189M 351M 23.38B 364M 2.3B 915M 11.26B 966M 946M 39.53B
Net Debt 1.95B 2.21B 283M 239M 218M 207M 385M 25.68B 400M 2.53B 1.01B 12.36B 1.06B 1.04B 43.41B 905M 1.02B 131M 110M 101M 96.09M 179M 11.89B 185M 1.17B 466M 5.73B 491M 481M 20.1B
Logo RemeGen Co., Ltd.
RemeGen Co Ltd is a China-based company primarily engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company’s main business is engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and other products. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company conducts its business in the domestic and overseas markets.
Employees
2,999
Date Price Change Volume
16/02/26 80.75 $ +0.56% 303,000
13/02/26 80.30 $ +0.06% 1,984,948
12/02/26 80.25 $ -1.71% 2,152,730
11/02/26 81.65 $ -1.03% 2,562,482
10/02/26 82.50 $ +3.64% 4,532,260
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
71.37CNY
Average target price
84.97CNY
Spread / Average Target
+19.05%

Quarterly revenue - Rate of surprise